196 related articles for article (PubMed ID: 19896446)
1. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
Sabarth N; Howard MK; Savidis-Dacho H; van Maurik A; Barrett PN; Kistner O
Vaccine; 2010 Jan; 28(3):650-6. PubMed ID: 19896446
[TBL] [Abstract][Full Text] [Related]
2. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
3. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
4. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
[TBL] [Abstract][Full Text] [Related]
5. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
6. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
Sabarth N; Savidis-Dacho H; Schwendinger MG; Brühl P; Portsmouth D; Crowe BA; Kistner O; Barrett PN; Kreil TR; Howard MK
Vaccine; 2012 Aug; 30(37):5533-40. PubMed ID: 22749797
[TBL] [Abstract][Full Text] [Related]
7. Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination.
Hwang SD; Shin JS; Ku KB; Kim HS; Cho SW; Seo SH
Vaccine; 2010 Apr; 28(17):2957-64. PubMed ID: 20188684
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
9. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
[TBL] [Abstract][Full Text] [Related]
11. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
[TBL] [Abstract][Full Text] [Related]
12. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
[TBL] [Abstract][Full Text] [Related]
13. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
15. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
17. Differences in the priming effect of various clades/subclades of inactivated H5N1 vaccine for booster injection with heterologous clades of vaccine strains.
Ikeno D; Kimachi K; Ibaragi K; Kudo Y; Goto S; Odoh K; Itamura S; Odagiri T; Tashiro M; Kino Y
Vaccine; 2011 May; 29(24):4156-61. PubMed ID: 21497637
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
20. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
